Royal Bank of Canada Downgrades Enanta Pharmaceuticals (ENTA) to Sector Perform

Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by research analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a research report issued on Tuesday, January 2nd, Marketbeat.com reports. They presently have a $54.00 price objective on the biotechnology company’s stock. Royal Bank of Canada’s target price would suggest a potential downside of 18.18% from the stock’s current price.

Several other research firms also recently commented on ENTA. TheStreet upgraded shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, JMP Securities increased their target price on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $45.25.

Enanta Pharmaceuticals (ENTA) opened at $66.00 on Tuesday. Enanta Pharmaceuticals has a 1-year low of $25.92 and a 1-year high of $66.02. The stock has a market cap of $1,260.00, a P/E ratio of 82.50 and a beta of 0.64.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business had revenue of $75.93 million during the quarter, compared to the consensus estimate of $73.80 million. During the same period in the prior year, the firm earned ($0.09) EPS. The business’s revenue for the quarter was up 491.3% compared to the same quarter last year. equities research analysts forecast that Enanta Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. GAM Holding AG acquired a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $108,000. Municipal Employees Retirement System of Michigan grew its position in Enanta Pharmaceuticals by 3.5% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 110 shares during the period. SG Americas Securities LLC grew its position in Enanta Pharmaceuticals by 5.8% in the 2nd quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares during the period. BNP Paribas Arbitrage SA grew its position in Enanta Pharmaceuticals by 62.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,702 shares during the period. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at $220,000. 66.83% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Royal Bank of Canada Downgrades Enanta Pharmaceuticals (ENTA) to Sector Perform” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://ledgergazette.com/2018/01/19/royal-bank-of-canada-downgrades-enanta-pharmaceuticals-enta-to-sector-perform.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply